Survival of the Fittest: Darwinian Selection Underpins Chemotherapy Resistance in AML

Publication date: 7 September 2017
Source:Cell Stem Cell, Volume 21, Issue 3
Author(s): Laura MacPherson, Mark A. Dawson
Intratumor heterogeneity driving therapeutic resistance is a major challenge in cancer management. Recently in Nature, Shlush et al. (2017) provide a tour de force of genomics coupled to functional assays to demonstrate that resistance emerges from a pre-existing subpopulation of acute myeloid leukemia (AML) cells with a stem cell transcription program.

Teaser

Intratumor heterogeneity driving therapeutic resistance is a major challenge in cancer management. Recently in Nature, Shlush et al. (2017) provide a tour de force of genomics coupled to functional assays to demonstrate that resistance emerges from a pre-existing subpopulation of acute myeloid leukemia (AML) cells with a stem cell transcription program.


http://ift.tt/2ePV1n7